Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT03773965

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Conditions: Juvenile Idiopathic Arthritis

Sex: All

Ages: 1 Year – 18 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 190

Sponsor: Eli Lilly and Company

Location: Instituto CAICI SRL Rosario

Summary

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Eligibility Criteria

Inclusion Criteria: * Participants must have completed a previous study of baricitinib for the treatment of JIA. Exclusion Criteria: * Participants must not have had a permanent discontinuation of baricitinib in the prior study. * Participants must have not developed an allergy to baricitinib.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03773965). StuddyBuddy aggregates publicly available trial information.